| |
IQVIA data scientists have created a framework, known as CASTER, to help you identify potential negative drug-drug interactions and account for them during the drug design process. Download the Insight Brief.
|
|
| By Kevin Dunleavy Promising heart data for Novo Nordisk's Wegovy are a "paradigm shift," according to J.P. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032. The analysts project Novo and Eli Lilly will dominate the market. |
|
|
|
By James Waldron Roche has installed “stronger gates” to ensure that drug candidates only make it into phase 3 trials if they have a high chance of success, CEO Thomas Schinecker has revealed. |
By Fraiser Kansteiner The companies included in the warning letter sweep are: Boiron, CVS Health, DR Vitamin Solutions, Natural Ophthalmics, OcluMed, Similasan, TRP Company and Walgreens Boots Alliance. |
By Max Bayer After tweaking the formula behind an mRNA flu vaccine, Moderna has finally met all the goals needed for a successful shot in a phase 3 trial. Now, CEO Stéphane Bancel is eyeing a launch as early as 2024. |
|
Tuesday, September 19, 2023 | 11am ET / 8am PT In this webinar, discover the rise of omnichannel engagement in life sciences and how the blend of in-person and digital channels is reshaping the industry. Learn from the IQVIA Brand Impact™ survey insights, understand the challenges in strategy execution, and explore how to achieve excellence in customer engagement. Register now.
|
|
By Gabrielle Masson Right after making headlines for a phase 3 mRNA flu shot win, Moderna shared that it’s axing four clinical assets from its pipeline—including two AstraZeneca dumped last year. |
By Angus Liu AbbVie’s next-generation anti-inflammation drug Skyrizi has been acing clinical trials left and right. The latest? The antibody drug is applying pressure on Johnson & Johnson’s Stelara with a successful head-to-head study in Crohn’s disease. |
By Conor Hale The spine and orthopedics company said that President and CEO Keith Valentine, Chief Financial Officer John Bostjancic and Chief Legal Officer Patrick Keran will be replaced, effective immediately. |
By Nick Paul Taylor Pfizer CEO Albert Bourla has thrown his weight behind a disease awareness campaign, using his handles on social media platforms to amplify messaging about the importance of migraine-friendly work policies. |
By Helen Floersh While science is still a long way off from using animals as incubators for human organs—a prospect that's rife with ethical dilemmas—the development marks a milestone for transplant medicine. |
By Zoey Becker A potentially dangerous crystal formation was found in a bottle of the drug, which is used to prevent organ rejections in transplant patients. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Wednesday, September 20th, 2023 | 2pm ET / 11am PT Patients are feeling empowered by digital health solutions, and a survey by Medisafe shows that that Pfizer, Abbott, AstraZeneca, and Bayer are among the top pharma companies leading the way in digital solutions. Join us to hear exactly what patients, HCPs and pharma professionals want brands to provide in their digital solutions to ensure patient engagement and impact. Register now.
|
|
| Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Whitepaper Discover five creative and innovative ways to reimagine your legacy biopharma campus and unlock value. Sponsored by: JLL |
| WhitepaperLearn how pharma marketers and other players in the industry can ease the way for consumers, ultimately improving health outcomes and boosting adherence in five simple steps. Sponsored by: Healthline Media |
| WhitepaperLearn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
| WhitepaperFrom trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| WhitepaperLearn how to close the knowledge gap for cancer patients by increasing awareness of important aspects of their condition, treatment options and support resources. Sponsored by: Phreesia Life Sciences |
| WhitepaperBy 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
| Whitepaper15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperUnravel the intricacies of Cell Line Development in biotherapeutics production with our latest eBook chapter. Sponsored By: Danaher Life Sciences |
| WhitepaperLearn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Sponsored by: Thermo Fisher Scientific Process Liquid Preparation Services |
| |
|
